Kyverna Therapeutics, Inc. (KYTX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -41.6M | -33.53M | -43.32M | -31.95M | -44.91M | -37.06M | -27.49M | -24.18M | -25.52M | -18.56M | -11.13M | -11.26M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 7.39% | 9.54% | -57.59% | -32.16% | -75.96% | -99.65% | -146.94% | -114.76% | - | - | - | - |
| Net Income | -39.73M | -37.8M | -36.79M | -42.08M | -44.63M | -37.49M | -34.49M | -28.8M | -26.69M | -20.67M | -15.46M | -13.09M |
| Depreciation & Amortization | 351K | 368K | 415K | 515K | 501K | 563K | 558K | 530K | 482K | 462K | 438K | 413K |
| Stock-Based Compensation | 0 | 2.7M | 2.7M | 2.52M | 2.16M | 1.38M | 3.41M | 1.28M | 2.28M | 784K | 521K | 447K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.17M | -527K | -795K | -1.13M | -758K | -1.55M | -2.22M | -1.59M | 246K | -151K | 4K | 446K |
| Working Capital Changes | -5.39M | 1.73M | -8.85M | 8.23M | -2.18M | 34K | 5.25M | 4.41M | -1.84M | 1.01M | 3.37M | 528K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 6.28M | 2.15M | -6.8M | 1.41M | 3.78M | -5.3M | 5.07M | -2.1M | 3.07M | 2.98M | 509K | 490K |
| Cash from Investing | -50.2M | -17.29M | 22.56M | 29.17M | 5.58M | 29.22M | 676K | -67.92M | -122.88M | 31.68M | -54.12M | -3K |
| Capital Expenditures | 0 | 1K | -392K | -4K | 0 | -532K | -102K | -1.03M | -543K | -334K | -256K | -3K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 70K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -1.01M | 0 | -200K | 2.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -101K | 140.74M | 1.49M | -649K | -414K | -215K | -152K | -569K | 338.05M | -1.43M | 34.79M | 24.91M |
| Debt Issued (Net) | -86K | 24.61M | -120K | -262K | -341K | -247K | -242K | -236K | -231K | -219K | -205K | -189K |
| Equity Issued (Net) | 174K | 116.18M | 1.65M | -336K | -73K | 32K | 90K | -333K | 341.17M | 0 | 34.84M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -189K | -50K | -43K | -51K | 0 | 0 | 0 | 0 | -2.89M | -1.22M | 154K | 25.09M |
| Net Change in Cash | -91.9M | 89.93M | -19.28M | -3.43M | -39.75M | -8.04M | -26.95M | -92.67M | 189.65M | 11.68M | -30.46M | 13.65M |
| Free Cash Flow | -41.6M | -33.52M | -43.71M | -32.15M | -44.91M | -37.59M | -27.59M | -25.2M | -26.07M | -18.9M | -11.39M | -11.26M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 7.39% | 10.83% | -58.43% | -27.58% | -72.3% | -98.94% | -142.28% | -123.83% | - | - | - | - |
| FCF per Share | -0.69 | -0.71 | -1.01 | -0.74 | -1.04 | -0.87 | -0.64 | -0.58 | -1.10 | -0.44 | -0.26 | -0.26 |
| FCF Conversion (FCF/Net Income) | 1.05x | 0.89x | 1.18x | 0.76x | 1.01x | 0.99x | 0.80x | 0.84x | 956.24x | 0.90x | 0.72x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 18K | 0 | 0 | 0 | 0 | 44K | 47K | 50K | 46K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |